Cancer in patients with pure PMR or RS3PE.
| Sex/Age, yrs | Diagnosis | Time Interval*, mo | Type of Malignancy | Initial Corticosteroid, mg/day | Response to Corticosteroid |
|---|---|---|---|---|---|
| 1 F 76 | RS3PE | +5 | Bladder cancer | 10 | Good |
| 2 M 85 | Pure PMR | +5 | CUP | 10 | Good |
| 3 F 75 | Pure PMR | +6 | MPD | 20 | Good |
| 4 F 86 | Pure PMR | +1 | Uterine cancer | 10 | Good |
| 5 F 71 | Pure PMR | −5 | Paget’s disease | 20 | Good |
| 6 M 80 | Pure PMR | −6 | Gastric cancer | 30 | Good |
| 7 F 75 | Pure PMR | −4 | Carotid body tumor | 10 | Good |
| 8 M 83 | RS3PE | −1 | Colon cancer | 20 | Good |
| 9 F 68 | Pure PMR | −10 | HCC | 30 | Good |
↵* Time interval from diagnosis of PMR or RS3PE to malignancy indicated in months (– and + indicate diagnosis of malignancy was given before or after diagnosis of RS3PE or pure PMR, respectively). RS3PE: remitting seronegative symmetrical synovitis with pitting edema; PMR: polymyalgia rheumatica; MPD: myeloproliferative disease; HCC: hepatocellular carcinoma; CUP: cancer of unknown primary origin.